Physicians' Academy for Cardiovascular Education

First-in-human trial results of PCSK9 gene editing therapy in HeFH and ASCVD

News - Nov. 13, 2023

Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol – Interim Results of the Phase 1b heart-1 Trial

Presented at the AHA Scientific Sessions 2023 by: Andrew Bellinger, MD, PhD- Boston, MA, USA

Introduction and methods

Currently, most patients treated for heterozygous familial hypercholesterolemia (HeFH) do not achieve LDL-c targets. VERVE-101 is a novel CRISPR base editing therapy that inactivates the hepatic PCSK9 gene and thereby lowers LDL-c levels. The interim results from the first-in-human trial of VERVE-101 in patients with HeFH and established ASCVD were presented at the meeting.

The heart-1 trial is an ongoing, open-label, single-ascending dose, phase 1b study designed to assess the safety and tolerability of VERVE-101. The interim analysis included 10 adult HeFH patients with severe, advanced ASCVD and high CVD risk (both short-term and lifetime), and elevated LDL-c levels despite maximum-tolerated oral lipid-lowering therapy. After pre-medication with dexamethasone and antihistamines, a single dose of VERVE-101 was administered via peripheral intravenous infusion across 4 escalating-dose cohorts (0.1, 0.3, 0.45, and 0.6 mg/kg).

The primary endpoints were safety and tolerability. Additional endpoints were pharmacokinetics and percent change of blood levels of PCSK9 protein and LDL-c from baseline to 28 days.

Main results


Administration of VERVE-101 resulted in dose-dependent reductions in blood levels of PCSK9 (up to 84%) and LDL-c (up to 55%) in 10 HeFH patients with ASCVD and uncontrolled hypercholesterolemia. The safety profile supported continued development of the therapeutic agent.

More patients are to be enrolled in the 0.45- and 0.6-mg/kg dose cohorts. The investigators plan to conduct a placebo-controlled phase 2 RCT with VERVE-101 in 2025.

- Our reporting is based on the information provided at the AHA Scientific Sessions 2023 -

Share this page with your colleagues and friends: